Roth Sees Visibility in Cytokinetics' (CYTK) CK-107 Program Increasing Significantly Moving Forward
Get Alerts CYTK Hot Sheet
Rating Summary:
18 Buy, 3 Hold, 0 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Roth Capital comments on Cytokinetics (Nasdaq: CYTK) following news that the company and Astellas are prepping for the Phase II program for CK-2127107 (CK-107) following the completion of five Phase I studies by Cytokinetics. Roth has Cytokinetics at Buy with a price target of $13.
Analyst Joseph Pantginis commented, We expect the CK-107 to increase significantly in visibility going forward, especially with the validation of having Astellas as a partner. The collaboration with Astellas was formed in June 2013 with Cytokinetics to receive over $40 million upfront payments ($16 million license fee and $24 million in R&D reimbursement over two years). Cytokinetics can receive over $450 million in milestone payments as well as royalties. Cytokinetics also has an option to copromote in North America. To highlight our levels of conservatism, we currently do not include CK-107 in our valuation of Cytokinetics.
For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.
Cytokinetics closed at $3.07 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cytokinetics (CYTK) option IV amid wide price movement
- Teleperformance (TEP:FP) (TLPFY) PT Lowered to EUR125 at RBC Capital, 'perceived risk profile makes it a no-fly zone for many investors'
- TD Cowen Starts Grindr (GRND) at Buy
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!